Catia Traversari

This inventor holds 23 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Ludwig Institute for Cancer Research Limited, Glycostem Therapeutics B.v., Ludwig Institute. Active years: 1994-2025.

USPTO Granted Patents = 23 (Patent Applications = 1)

% Patents Active = 95.7

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 5.5

ph-index = 11

Forward Citations = 372(Granted Patents)

Company Filing History:

19 out of 530

Ludwig Institute for Cancer Research Limited

patents

1 out of 3

Glycostem Therapeutics B.v.

5. 1 out of 834,453

Other

patents

Years Active: 1994-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12304962 - CAR NK cells (2025-05-20),

2. 7923534 - Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 (2011-04-12),

3. 7413733 - Antigen transduced T cells used as a delivery system for antigens (2008-08-19),

4. RE40089 - Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor (2008-02-18),

5. 6531451 - Tumor antigens and CTL clones isolated by a novel procedure (2003-03-11),

6. 6488932 - Method for treating cancer by administering MAGE-derived peptides (2002-12-03),

7. 6379901 - Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules (2002-04-30),

8. 6353089 - Method for stimulating CTLs with peptides (2002-03-05),

9. 6222012 - Isolated nonapeptides presented by HLA molecules, and uses thereof (2001-04-24),

10. 6201111 - Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors (2001-03-13),

11. 6034214 - Isolated nonapeptides which bind to HLA molecules and provoke lysis by (2000-03-07),

12. 6019987 - Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules (2000-02-01),

13. 6001975 - Precursor processed to at least one tumor rejection antigen presented by (1999-12-14),

14. 5925729 - Tumor rejection antigen precursors, tumor rejection antigens and uses (1999-07-20),

15. 5856091 - Isolated nucleic acid sequence coding for a tumor rejection antigen (1999-01-05),

Title: Catia Traversari - Innovative Inventor from Milan

Introduction: Catia Traversari is a pioneering inventor hailing from Milan, Italy, known for her groundbreaking contributions to various fields through her innovative patents.

Latest Patents: Catia Traversari's latest patents include advancements in renewable energy technologies, sustainable materials, and medical devices, showcasing her diverse range of expertise and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Catia Traversari has established herself as a prominent figure in the world of innovation, holding numerous patents that have significantly impacted industries worldwide.

Collaborations: Throughout her career, Catia Traversari has collaborated with leading research institutions, universities, and companies to bring her inventions to life, fostering a culture of innovation and collaboration in the process.

Conclusion: Catia Traversari's relentless pursuit of innovation and her passion for creating solutions to complex challenges have solidified her reputation as a visionary inventor, inspiring the next generation of innovators to push the boundaries of what is possible.